Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
- Publication date
- 1 May 2018
- Publisher
- Barrow - St. Joseph\u27s Scholarly Commons